RankAlpha logo
Back to Rankings

AMRX

AmnealA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Amneal has shown broad-based revenue and EBITDA growth, raised full-year guidance, reduced prospective interest expense, and has a potential biosimilars growth platform through Kashiv. The $21 median analyst target implies upside from the $17.05 anchor, but the target count is unavailable.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +9.2.
What can break
Amneal remains exposed to generic-drug pricing pressure and execution across a diversified portfolio.
Momentum
43
Value
63
Sentiment
81
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $20.00 · Bull $24.00 · Bear $13.50Analysis 2026-09-09; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-09 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-09-09

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions

Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $21.33
Why
Momentum43 · Δ7d +8.9
Value63 · Δ7d 0.0
Sentiment81 · Δ7d +9.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • Sentiment remains the lead driver in the composite, 7D delta +9.2.

Contradictions & invalidation

  • • Amneal remains exposed to generic-drug pricing pressure and execution across a diversified portfolio.
  • • Kashiv closing, financing, integration, and U.S. regulatory milestones may not occur as expected; contingent payments of up to $350 million depend on milestones for six candidates. [#8-K-2026-08-10]
  • • The Kashiv opportunity remains execution- and regulatory-dependent, leverage remains material, generic pharmaceuticals face pricing pressure, and recent director/officer sales may weigh on sentiment.

Catalyst clock

2026-09-30

Q2 momentum and raised FY2026 guidance execution

Lead driver: Sentiment · See AI snapshot
Momentum
43
9% active weight
Current posture
7d trendImproving
Δ7d
+8.9
Δ21d
-36.2
Value
63
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-1.0
Sentiment
81
62% active weight
Current posture
7d trendImproving
Δ7d
+9.2
Δ21d
+6.8
Why this grade

Composite grade A. Momentum 42.9 / Value 63.1 / Sentiment 81.1

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-09. Scenario method

B+
Bull case
25%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
Most likely
B
Base case
55%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$13.50
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$5.88B
Beta
1.36
Shares Out
319.35M
P/E (TTM)
769.4
P/S (TTM)
1.36
P/FCF (TTM)
16.89
Rev YoY
+9.9%
EPS YoY
+152.8%
Gross Margin
+39.3%
Op Margin
+15.3%
Net Debt
$2.38B
Current Ratio
2.20
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data